Abstract 577P
Background
Dysbiosis of the fecal microbiota has been closely related to colorectal cancer (CRC) and has increasingly proven to be associated with CRC prognosis. However, a significant knowledge gap still exists regarding intestinal tissue-resident microbes and their associations with host genetic alterations, gene expressions and prognosis in CRC.
Methods
We undertook a comprehensive analysis of the tissue-resident microbes in CRC patients from the U-CAN cohort, a large prospective longitudinal study of adult cancer patients in Sweden, using treatment-naïve whole-genome (average 53x coverage) and whole-transcriptome sequencing data of tumors (n=937) and their adjacent normal tissues (n=475).
Results
In total, 301 genera and 420 species were identified as common tissue-resident taxa. We showed for the first-time distinct enrichment patterns of tissue-resident microbiome in the right- and left-sided colons. Importantly, these patterns were highly consistent between tumor and normal tissues, with right-sided colons enriched with Clostridium spp and left-sided colons enriched with Akkermansia muciniphila and Bifidobacterium spp. We identified 94 tumor-enriched bacteria, and 38 were significantly associated with host hypermutation (HM) status. Previously known CRC-enriched bacteria, such as Fusobacterium groups and Campylobacter, were more prevalent in right-sided and HM tumors, and strongly correlated with mutations in host drivers and DNA damage repair genes. CRC driver genes that correlated with identified intratissue bacteria including CASP8, TP53 and SMAD2, with CASP8 significantly associated with multiple CRC-enriched taxa in all and in HM samples. Finally, risk scores derived from tumor or normal-resident taxa could both predict CRC prognosis and significantly improve the prognosis performance of the consensus molecular subtypes (CMS).
Conclusions
Our study provides new insights into the interactions between tumor-enriched microbiota with CRC and identifies potential bacteria markers that could improve the accuracy of CRC prognosis prediction. These findings can guide future efforts to exploit the performance of intratissue bacteria on CRC prognosis prediction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University, Umea University, BGI-Shenzhen.
Funding
The Swedish Cancer Society, the Uppsala Cancer Foundation, the Guangdong Provincial Key Laboratory of Human Disease Genomics, the Swedish Government (CancerUU), the Erling-Persson Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
548P - Diffuse midline gliomas H3K27-altered in adults, the experience of an oncology center
Presenter: Carolina Trabulo
Session: Poster session 10
561P - Risk of colorectal cancer and premalignant lesions after kidney transplantation
Presenter: Koen Zwart
Session: Poster session 10
562P - Quantifying the effect of colonoscopy and polypectomy rates in stage shift of colorectal cancer and reduced need for adjuvant chemotherapy
Presenter: Mina Sarofim
Session: Poster session 10
563P - The impact of participation in colorectal cancer screening: A population-based results from Lithuania
Presenter: Tomas Poskus
Session: Poster session 10
564P - A large-scale real-world study for colorectal cancer screening
Presenter: Song LIU
Session: Poster session 10
565P - Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
Presenter: Doreen Gisder
Session: Poster session 10
566P - Long-term survivorship outcomes of adolescents and young adults (AYA) with cancer of the lower gastrointestinal tract
Presenter: Winette Van Der Graaf
Session: Poster session 10
567P - Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
Presenter: Elisabeth Bergen
Session: Poster session 10
568P - Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial
Presenter: Faiz Jabbar
Session: Poster session 10
569P - Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
Presenter: Frank Sinicrope
Session: Poster session 10